Chloroquine (CQ) is no longer effective for treating P. falciparum due to widespread resistance, prompting a shift in drug policies, which was analyzed in malaria-endemic regions of West Bengal, India.
In a study involving 781 P. falciparum patients from 2008 to 2013, chloroquine resistance was linked to specific genetic markers, with high rates of treatment failure and recrudescence reported.
Over the years, in vitro resistance rates rose significantly, necessitating increased research and containment efforts to address the persistent problem of chloroquine resistance even after its withdrawal as a treatment option.